

Contact: Liz Dowling
Liz@DowlingDennis.net
760-822-3412
Dowling and Dennis Public Relations

Parker Laboratories to Introduce Groundbreaking Ultrasound Innovations at AVA 2023

UltraDrape II and Tristel ULT promote patient safety while reducing costs and increasing efficiency for ultrasound-guided percutaneous procedures

FAIRFIELD, NJ—Parker Laboratories Inc., a worldwide leader in ultrasound supplies and accessories, is launching two innovative ultrasound products designed to increase patient safety, lower costs and improve workflow in busy healthcare settings that rely on point-of-care ultrasound. The company will introduce the UltraDrape[®] II UGPIV Barrier and Securement Dressing and Tristel ULT™ high-level disinfectant foam at the upcoming <u>Association for Vascular Access 2023 Annual Scientific Meeting</u>.

Ultrasound technologies offer important advantages for vascular access procedures such as inserting central lines and peripheral catheters, improving outcomes while also reducing risks and healthcare costs. Hospitals are seeing an increase in the number of patients with difficult vascular access (DiVA) that require ultrasound guidance to achieve peripheral vascular access. It is estimated there are 12 million ultrasound-guided peripheral IV (UGPIV) insertions performed annually in North America.

"As the use of ultrasound guidance for vascular access procedures increases, so does the need for supplies that make these procedures safer and more efficient, without increasing costs," said Neal Buchalter, president of Parker Laboratories. "These new products are just a few of the innovative and cost-effective solutions we are committed to bring to market to increase patient safety and improve workflow for busy vascular access clinicians."

About UltraDrape II Barrier and Securement Dressing

<u>UltraDrape II</u> is the next generation of Parker's groundbreaking <u>UltraDrape®</u>, the only dressing designed specifically for use during UGPIV procedures. Like the original, UltraDrape II is a sterile, dual-action barrier and securement dressing that provides a "gel-free" insertion site to decrease the risk of contamination and securement failure both during and after UGPIV procedures.

Based on user feedback, UltraDrape II was designed to offer several additional advantages:

• **Broader Use** - Smaller size allows for use on a broader patient population.

- Easier to Use New FlexTab™ improves "standability," creating a secure barrier between the ultrasound transducer and the skin. The quick-release film allows for immediate and residue-free gel removal.
- **Improved Visualization** Features a borderless end for ease of scanning in both long and short axis, and allows imaging beyond the dressing.

The innovative dressing is also more <u>cost-effective</u> when compared to other UPGIV protocols, such as sterile gels and covers.

About Tristel ULT High-Level Disinfectant Foam

<u>Tristel ULT</u> is a high-level disinfectant that uses a unique, proprietary foam containing chlorine dioxide for reprocessing ultrasound probes. It was recently granted FDA <u>clearance</u> for use as a high-level disinfectant for ultrasound probes used within body cavities and for skin-surface transducers, making it the first product of its kind to be available in the United States.

More than 215 million ultrasound scans are performed in the U.S. each year, with approximately 20% of them requiring high-level disinfection. Tristel ULT is the only high-level disinfectant foam that can be safely used on ultrasound probes, and it has been shown to be effective against pathogens ranging from SARS-CoV-2 to *Mycobacterium tuberculosis*.

As a rapid and inexpensive high-level disinfectant, Tristel ULT represents an important advance offering several advantages over other methods of high-level disinfection currently on the market:

- **Fast** Fastest kill time for a high-level disinfectant (2 minutes at room temperature)
- **Economical** Doesn't require dedicated facilities, capital investment, electrical/plumbing connections or reserve units
- **Easy to Use** Compact, portable, closest to point-of-care and ready-to-use; unique design/dispensing system also guarantees accurate dosing

Tristel ULT is manufactured and distributed for North America markets by Parker Laboratories under an exclusive commercial partnership with UK-based Tristel plc (AIM: TSTL). Full US product launch and market availability of Tristel ULT is scheduled for October 2023.

The 2023 AVA Scientific Meeting will take place October 14-17, 2023, in Portland, Ore. To learn more about UltraDrape II and Tristel ULT, visit Parker Laboratories at BOOTH #708

About Parker Laboratories

Parker Laboratories is a leading global medical product company that develops, manufactures, and sells ultrasound and electromedical contact media and accessories, as well as leading lines of instrument cleaners and disinfectants. A worldwide leader in ultrasound medical products for over 65 years, Parker has consistently been at the forefront of technological advances in the industry. Its flagship product, Aquasonic®100 ultrasound transmission gel, is the world standard for medical ultrasound. For more information, visit www.parkerlabs.com.